CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 29 enrolled
Drug / intervention
Saline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02779075
NCT02779075N/ACompleted
CompareCT.gov

Exendin-9,39 and Satiety After Bariatric Surgery

Mayo Clinic·interventional·Posted May 20, 2016·Updated May 1, 2020

In Brief

A clinical study evaluating Saline and Exendin-9,39 for Obesity. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The overall aim of the application is to determine the contribution of the elevated incretin hormone concentrations seen after certain types of bariatric surgery to the regulation of food intake and satiety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsThe Obesity Society

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 20, 2016
Enrollment StartJun 1, 2016
Primary CompletionJul 1, 2019
Study CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.1 years ago

Interventions

Salinedrug

Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.

Exendin-9,39drug

Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.